Efficacy and safety of decamethoxin in complex treatment of patients with group III viral-bacterial community-acquired pneumonia
BACKGROUND. There are many unsolved medical problems and, of course, pneumonia is one of them. Communityacquired pneumonia (CAP) is a multifactorial disease, but the role of viruses as causative agents is constantly growing. Specific antiviral therapy for CAP is limited. Therefore, the search for dr...
Saved in:
Main Author: | O.L. Bororova (Author) |
---|---|
Format: | Book |
Published: |
Civic Union "Communicable Diseases Intensive Care Association",
2021-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Diagnostics of complicated course of community-acquired pneumonia of viral etiology (COVID-19) via using chest computed tomography
by: М.І. Lynnyk, et al.
Published: (2021) -
The research of antibacterial properties of decamethoxin, decasan, horosten
by: H. K. Palii, et al.
Published: (2019) -
The research of antibacterial properties of decamethoxin, decasan, horosten
by: H. K. Palii, et al.
Published: (2019) -
Procalcitonin for detecting community-acquired bacterial pneumonia
by: Devi Gusmaiyanto, et al.
Published: (2015) -
Comparative efficacy and safety analysis of CSE-1034: An open labeled phase III study in community acquired pneumonia
by: Manu Chaudhary, et al.
Published: (2018)